Patents Assigned to Neose Technologies, Inc.
-
Publication number: 20100261872Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: December 21, 2006Publication date: October 14, 2010Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
-
Publication number: 20100143969Abstract: The present invention provides enhanced methods of producing soluble, active eukaryotic glycosyltransferases in prokaryotic microorganisms that have an oxidizing environment.Type: ApplicationFiled: March 24, 2006Publication date: June 10, 2010Applicant: Neose Technologies, Inc.Inventors: Marc F. Schwartz, Tarik Soliman
-
Publication number: 20100009902Abstract: The present invention provides conjugates between a substrate, e.g., peptide, glycopeptide, lipid, etc., and a modified saccharyl fragment bearing a modifying group such as a water-soluble polymer, therapeutic moiety or a biomolecule. The conjugates are linked via the enzymatic conversion of the activated modified saccharyl fragment into a glycosyl linking group that is interposed between and covalently attached to the substrate and the modifying group. The conjugates are formed from substrates by the action of a sugar transferring enzyme, e.g., a glycosyltransferase. For example, when the substrate is a peptide, the enzyme conjugates a modified saccharyl fragment moiety onto either an amino acid or glycosyl residue of the peptide. Also provided are pharmaceutical formulations that include the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: January 6, 2006Publication date: January 14, 2010Applicant: NEOSE TECHNOLOGIES, INC.Inventor: Shawn DeFrees
-
Patent number: 7569376Abstract: This invention provides recombinant glycosyltransferase fusion proteins having a desired level of expression and enzymatic activity (for example, acceptor substrate specificity or catalytic activity). The fusion proteins of the invention have a functional domain of a first glycosyltransferase joined, directly or through a peptide linker, to a subsequence of a functional domain of a second glycosyltransferase. Nucleic acids that encode the fusion proteins are also provided, as are host cells for expressing the fusion proteins and methods of making and using the fusion proteins of the invention.Type: GrantFiled: May 5, 2003Date of Patent: August 4, 2009Assignee: Neose Technologies, Inc.Inventors: Robert J. Bayer, Grace Mendoza
-
Publication number: 20090176278Abstract: The present invention provides reaction mixtures comprising a solvent having at least one of an alkoxy ether and/or a polyhydric alcohol for use in reactions with a mutant endoglycoceramidase having enhanced synthetic activity.Type: ApplicationFiled: December 1, 2006Publication date: July 9, 2009Applicant: NEOSE TECHNOLOGIES, INC.Inventors: Shawn Defrees, Xiaoping Tang
-
Publication number: 20090143292Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: ApplicationFiled: August 29, 2008Publication date: June 4, 2009Applicants: Neose Technologies, Inc., BioGeneriX AGInventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20090137763Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: April 11, 2008Publication date: May 28, 2009Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David Zopf, Robert Bayer, Caryn Bowe, David Hakes, Xi Chen
-
Patent number: 7524655Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.Type: GrantFiled: December 6, 2005Date of Patent: April 28, 2009Assignees: Neose Technologies, Inc., Governors of the University of AlbertaInventors: Karl F. Johnson, Daniel James Bezila, Diane E. Taylor, Joanne Simala-Grant, David Rasko
-
Publication number: 20090093399Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: January 24, 2007Publication date: April 9, 2009Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
-
Publication number: 20090081188Abstract: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: August 1, 2008Publication date: March 26, 2009Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
-
Publication number: 20090053167Abstract: The present invention provides polypeptide conjugates wherein a modifying group such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked to the polypeptide through a glycosyl linking group. In one embodiment, the polypeptide includes a glycosylation consensus sequence, wherein glycosylation occurs at an aromatic amino acid residue, such as the C-2 or the N-1 position of a tryptophan side chain. Exemplary polypeptides of the invention are those in which the glycosylation consensus sequence has been introduced into the amino acid sequence of the polypeptide by mutation. In another aspect the invention provides polypeptide conjugates wherein the modifying group is covalently linked to the polypeptide via a glycosyl mimetic linking group. Also provided are methods of making and using as well as pharmaceutical compositions containing the polypeptide conjugates of the invention.Type: ApplicationFiled: May 14, 2008Publication date: February 26, 2009Applicant: Neose Technologies, Inc.Inventor: Shawn DeFrees
-
Publication number: 20090047710Abstract: The present invention features compositions and methods related to increasing the solubility and enzymatic activity of GalNAc-?-2,6-sialyltransferase I (STÌGalNAcI) proteins expressed in prokaryotic host cells. Methods for increasing the solubility of STÌGalNAcI polypeptides include modifying cysteine residues, modifying N-linked glycosylation sites, deleting polypeptide regions, and constructing chimeric polypeptides comprising sequences from a STÌGalNAcI and another protein, for example, a Gal-?-1,3GalNAc-?-2,3-sialyltransferase (ST3GalI) and a STÌGalNAcI. The invention also features nucleic acids encoding such improved polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.Type: ApplicationFiled: November 8, 2006Publication date: February 19, 2009Applicant: Neose Technologies, Inc.Inventor: Shawn DeFrees
-
Publication number: 20090048440Abstract: The invention provides methods of removing contaminants from a mixture of a desired product and contaminants by pH adjustments and molecular weight cut-offs. The contaminants include phosphate groups, magnesium sulfate, sodium pyruvate and tetrasodium pyrophosphate groups. The desired product includes nucleotide sugars, glycolipids, LnNT, sialyl lactose, and salts.Type: ApplicationFiled: November 3, 2006Publication date: February 19, 2009Applicant: Neose Technologies, Inc.Inventors: Michael Felo, Shawn DeFrees
-
Publication number: 20090028822Abstract: The present invention provides IFN-? conjugates including IFN-? peptides and modifying groups such as PEG moieties. The IFN-? peptide and modifying group are linked via an intact glycosyl linking group interposed between and covalently attached to the IFN-? peptide and the modifying group. The IFN-? conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar onto an amino acid or a glycosyl residue on the IFN-? peptide. Also provided are methods for preparing the IFN-? conjugates, methods for treating various disease conditions with the IFN-? conjugates, and pharmaceutical formulations including the IFN-? conjugates.Type: ApplicationFiled: September 12, 2005Publication date: January 29, 2009Applicant: NEOSE TECHNOLOGIES, INC.Inventors: Shawn DeFrees, David A. Zopf, Henrik Clausen, Ruye Xing
-
Patent number: 7473680Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.Type: GrantFiled: July 15, 2005Date of Patent: January 6, 2009Assignee: Neose Technologies, Inc.Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn Bowe, Xi Chen
-
Publication number: 20080319183Abstract: The present invention provides sugars, nucleotide sugars, activated sugars that include one or more polymeric modifying moiety within their structure. The invention is exemplified by reference to linear and branched polymers, such as the water-soluble polymer poly(ethylene glycol).Type: ApplicationFiled: January 26, 2005Publication date: December 25, 2008Applicant: NEOSE TECHNOLOGIES, INC.Inventors: Shawn DeFrees, Caryn Bowe
-
Publication number: 20080318850Abstract: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: May 6, 2004Publication date: December 25, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
-
Publication number: 20080305991Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: January 23, 2007Publication date: December 11, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David Zopf, Robert J. Bayer, Caryn Bowe, David Hakes, Xi Chen
-
Publication number: 20080305992Abstract: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: October 31, 2007Publication date: December 11, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, Robert J. Bayer, David A. Zopf
-
Publication number: 20080300175Abstract: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: October 31, 2007Publication date: December 4, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, Robert J. Bayer, David A. Zopf